Integrated BioPharma(INBP)
$0.17+0.01 (+4.38%)
INBP
Integrated BioPharma financials statements
$0.17
At close:+0.01 (+4.38%)
Want to see INBP full AI Analyst Report?
Integrated BioPharma (INBP) Ratios
10 Followers
Integrated BioPharma Ratios
INBP's free cash flow for Q1 2027 was $-1.34M. For the 2027 fiscal year, INBP's free cash flow was decreased by $-124.00K and operating cash flow was $-1.22M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.00 | 4.42 | 2.92 | 3.39 | 3.16 |
| Quick Ratio | 1.42 | 2.21 | 1.08 | 1.27 | 1.06 |
| Cash Ratio | 0.77 | 0.85 | 0.27 | 0.27 | 0.06 |
| Solvency Ratio | -0.19 | 0.45 | 0.19 | 0.17 | 0.70 |
| Operating Cash Flow Ratio | 0.21 | 0.49 | 0.15 | 0.26 | 0.78 |
| Short-Term Operating Cash Flow Coverage | 1.03 | 0.00 | 0.99 | 1.32 | 30.76 |
| Net Current Asset Value | $ 9.71M | $ 14.18M | $ 10.91M | $ 9.80M | $ 9.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.12 | 0.04 | 0.07 | 0.11 | 0.08 |
| Debt-to-Equity Ratio | 0.17 | 0.05 | 0.09 | 0.14 | 0.11 |
| Debt-to-Capital Ratio | 0.15 | 0.05 | 0.09 | 0.12 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.43 | 1.23 | 1.36 | 1.35 | 1.36 |
| Debt Service Coverage Ratio | -1.31 | 46.15 | 1.31 | 1.18 | 18.39 |
| Interest Coverage Ratio | -225.42 | 43.91 | 4.83 | 3.00 | 15.36 |
| Debt to Market Cap | 0.22 | 0.00 | 0.16 | 0.09 | 0.01 |
| Interest Debt Per Share | 0.10 | 0.04 | 0.06 | 0.09 | 0.07 |
| Net Debt to EBITDA | 1.06 | -0.77 | 0.08 | 1.06 | 0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 1.82% | 10.23% | 7.72% | 8.01% | 11.65% |
| EBIT Margin | -6.17% | 3.88% | 0.50% | 0.24% | 4.88% |
| EBITDA Margin | -3.00% | 6.21% | 2.93% | 2.51% | 6.33% |
| Operating Profit Margin | -6.17% | 3.72% | 0.50% | 0.24% | 3.50% |
| Pretax Profit Margin | -5.84% | 3.79% | 0.53% | 0.20% | 4.62% |
| Net Profit Margin | -6.48% | 1.49% | 0.22% | -0.07% | 6.82% |
| Continuous Operations Profit Margin | -6.48% | 1.49% | 0.22% | -0.07% | 6.82% |
| Net Income Per EBT | 110.89% | 39.19% | 41.79% | -34.00% | 147.79% |
| EBT Per EBIT | 94.75% | 102.08% | 106.77% | 83.33% | 132.10% |
| Return on Assets (ROA) | -11.22% | 3.24% | 0.43% | -0.13% | 15.20% |
| Return on Equity (ROE) | -16.09% | 3.98% | 0.58% | -0.18% | 20.66% |
| Return on Capital Employed (ROCE) | -13.85% | 9.78% | 1.25% | 0.58% | 9.84% |
| Return on Invested Capital (ROIC) | -13.04% | 3.71% | 0.48% | -0.18% | 9.53% |
| Return on Tangible Assets | -11.22% | 3.24% | 0.43% | -0.13% | 15.20% |
| Earnings Yield | -50.83% | 7.47% | 1.86% | -0.34% | 25.73% |
| Efficiency Ratios | |||||
| Receivables Turnover | 13.16 | 10.01 | 10.78 | 11.23 | 11.51 |
| Payables Turnover | 13.46 | 21.52 | 18.50 | 20.57 | 15.49 |
| Inventory Turnover | 4.71 | 5.21 | 4.13 | 4.54 | 4.50 |
| Fixed Asset Turnover | 9.09 | 19.77 | 13.69 | 11.85 | 14.89 |
| Asset Turnover | 1.73 | 2.18 | 1.92 | 1.99 | 2.23 |
| Working Capital Turnover Ratio | 3.36 | 4.14 | 4.32 | 4.42 | 5.59 |
| Cash Conversion Cycle | 78.09 | 89.54 | 102.52 | 95.10 | 89.35 |
| Days of Sales Outstanding | 27.74 | 36.46 | 33.86 | 32.49 | 31.72 |
| Days of Inventory Outstanding | 77.47 | 70.04 | 88.39 | 80.35 | 81.20 |
| Days of Payables Outstanding | 27.12 | 16.96 | 19.73 | 17.74 | 23.57 |
| Operating Cycle | 105.21 | 106.50 | 122.25 | 112.85 | 112.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.04 | 0.07 | 0.03 | 0.04 | 0.14 |
| Free Cash Flow Per Share | 0.03 | 0.06 | 0.01 | 0.04 | 0.12 |
| Dividend Paid and CapEx Coverage Ratio | 3.59 | 10.81 | 1.71 | 10.62 | 8.42 |
| Capital Expenditure Coverage Ratio | 3.59 | 10.81 | 1.71 | 10.62 | 8.42 |
| Operating Cash Flow Coverage Ratio | 0.40 | 2.03 | 0.52 | 0.46 | 1.99 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.04 | 0.02 | 0.02 | 0.07 |
| Free Cash Flow Yield | 16.01% | 17.33% | 6.49% | 11.29% | 24.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.97 | 13.37 | 53.69 | -290.69 | 3.89 |
| Price-to-Sales (P/S) Ratio | 0.13 | 0.20 | 0.12 | 0.20 | 0.27 |
| Price-to-Book (P/B) Ratio | 0.32 | 0.53 | 0.31 | 0.52 | 0.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.25 | 5.77 | 15.42 | 8.86 | 4.14 |
| Price-to-Operating Cash Flow Ratio | 4.51 | 5.24 | 6.38 | 8.02 | 3.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.02 | -0.12 | 2.88 | -0.07 |
| Enterprise Value Multiple | -3.19 | 2.43 | 4.17 | 8.82 | 4.68 |
| Enterprise Value | 4.20M | 8.22M | 6.13M | 11.24M | 16.64M |
| EV to EBITDA | -3.19 | 2.43 | 4.17 | 8.82 | 4.68 |
| EV to Sales | 0.10 | 0.15 | 0.12 | 0.22 | 0.30 |
| EV to Free Cash Flow | 4.69 | 4.38 | 15.73 | 10.07 | 4.62 |
| EV to Operating Cash Flow | 3.38 | 3.98 | 6.50 | 9.12 | 4.07 |
| Tangible Book Value Per Share | 0.57 | 0.67 | 0.64 | 0.63 | 0.62 |
| Shareholders’ Equity Per Share | 0.57 | 0.67 | 0.64 | 0.63 | 0.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.11 | 0.61 | 0.58 | 1.34 | -0.48 |
| Revenue Per Share | 1.41 | 1.79 | 1.67 | 1.69 | 1.88 |
| Net Income Per Share | -0.09 | 0.03 | 0.00 | -0.00 | 0.13 |
| Tax Burden | 1.11 | 0.39 | 0.42 | -0.34 | 1.48 |
| Interest Burden | 0.95 | 0.98 | 1.07 | 0.83 | 0.95 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Income Quality | -0.44 | 2.56 | 8.42 | -36.24 | 1.07 |
Currency in USD

